Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) by 28.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,702 shares of the company’s stock after selling 8,370 shares during the period. BNP Paribas Financial Markets’ holdings in Akero Therapeutics were worth $594,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in Akero Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after purchasing an additional 446 shares during the period. Eastern Bank acquired a new position in shares of Akero Therapeutics during the third quarter valued at $100,000. Summit Financial Wealth Advisors LLC acquired a new position in shares of Akero Therapeutics during the third quarter valued at $205,000. Victory Capital Management Inc. bought a new position in shares of Akero Therapeutics during the third quarter worth about $211,000. Finally, Quest Partners LLC increased its holdings in shares of Akero Therapeutics by 22,021.1% in the 2nd quarter. Quest Partners LLC now owns 12,609 shares of the company’s stock worth $296,000 after acquiring an additional 12,552 shares during the period.

Insider Activity

In other Akero Therapeutics news, VP Patrick Lamy sold 925 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $28,480.75. Following the transaction, the vice president now owns 17,858 shares in the company, valued at approximately $549,847.82. The trade was a 4.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Catriona Yale sold 2,485 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $27.52, for a total value of $68,387.20. Following the completion of the transaction, the insider now directly owns 75,294 shares in the company, valued at $2,072,090.88. This represents a 3.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 398,584 shares of company stock worth $12,430,272 over the last 90 days. 7.94% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on AKRO shares. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research note on Monday, November 18th. Citigroup started coverage on Akero Therapeutics in a research report on Monday, November 18th. They set a “buy” rating and a $65.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $46.83.

Akero Therapeutics Trading Down 0.5 %

Shares of NASDAQ:AKRO opened at $28.89 on Friday. The company has a 50 day moving average of $30.81 and a 200-day moving average of $27.08. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm has a market cap of $2.02 billion, a P/E ratio of -7.70 and a beta of -0.23. Akero Therapeutics, Inc. has a twelve month low of $15.32 and a twelve month high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). As a group, analysts anticipate that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.